Insider open-market buy by the founder/chairman is directionally positive for sentiment, but the small absolute size limits its conviction signal. Monitor upcoming Phase 2a data or pipeline catalysts for re-rating; the insider purchase alone is unlikely to move the stock significantly.
Price Chart
Executive Summary
Executive Chairman and Founder Gabriele Cerrone, through Panetta Partners Ltd, purchased 15,000 common shares at $1.11 per share, increasing his total holdings to 44,772,230 common shares (34.89% of issued share capital). This insider open-market buy signals alignment with shareholders but is relatively small ($16,650) for a $140M market cap company, making it a modest positive signal.
Key Facts
- Executive Chairman and Founder Gabriele Cerrone purchased 15,000 common shares at $1.11 per share
- Post-purchase, Cerrone (via Panetta Partners Ltd) holds 44,772,230 common shares, or 34.89% of issued share capital
- The open-market buy is a signal of insider confidence but the dollar amount ($16,650) is small relative to the ~$140M market cap
- Company is a clinical-stage biotech with lead candidate intranasal foralumab for non-active secondary progressive multiple sclerosis
Financial Impact
Total insider purchase of $16,650 — minimal direct financial impact; signaling value is the primary read.
Risk Factors
- Pre-revenue clinical-stage biotech with binary pipeline events (Phase 2a foralumab data)
- Small insider purchase ($16.6K) may not reflect strong conviction compared to larger positions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-068498 |
| Document: ea029475801ex99-1.htm | 0001213900-26-068498 |
| Document: 0001213900-26-068498-index-headers.html | 0001213900-26-068498 |
| Document: 0001213900-26-068498-index.html | 0001213900-26-068498 |
| Document: 0001213900-26-068498.txt | 0001213900-26-068498 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8934 (−11.54%) |
Oct 16, 2026 10d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8934 (+11.54%) |
Oct 16, 2026 11d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8934 (−14.91%) |
Sep 30, 2026 27d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8934 (−19.51%) |
Sep 28, 2026 29d ago | 6-K | $0.9800 $0.8850 | ▼ −9.69% | ▼ −9.66% | $0.8934 (−8.84%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8934 (−1.24%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8934 (−7.90%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8934 (−7.90%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8934 (−22.31%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8934 (−7.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers